Dopaminergic agents and stimulants as antidepressant augmentation strategies

Journal of Clinical Psychiatry

Volumn 59, Issue SUPPL. 5, 1998, Pages 60-64

  Nierenberg, Andrew A ^a   Dougherty, Darin ^b   Rosenbaum, Jerrold F ^b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; AMFEBUTAMONE; AMITRIPTYLINE; ANTIDEPRESSANT AGENT; BROMOCRIPTINE MESILATE; CENTRAL STIMULANT AGENT; DEXAMPHETAMINE; DOPAMINE RECEPTOR STIMULATING AGENT; FENFLURAMINE; FLUOXETINE; IMIPRAMINE; METHYLPHENIDATE; MONOAMINE OXIDASE INHIBITOR; PAROXETINE; PEMOLINE MAGNESIUM; PERGOLIDE MESILATE; TRAZODONE;

ARTICLE; CONFUSION; DEPRESSION; DOPAMINERGIC TRANSMISSION; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG RECEPTOR BINDING; DRUG TOLERANCE; DYSKINESIA; HALLUCINATION; HUMAN; NAUSEA; ORTHOSTATIC HYPOTENSION; PRIORITY JOURNAL; PSYCHOSIS; TACHYCARDIA; VOMITING; WEIGHT REDUCTION;

ANTIDEPRESSIVE AGENTS; CENTRAL NERVOUS SYSTEM STIMULANTS; DEPRESSIVE DISORDER; DOPAMINE AGENTS; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; HUMANS; PEMOLINE; PRACTICE GUIDELINES;

EID: 0031811285     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Kapur S, Mann JJ. Role of the dopaminergic system in depression. Biol Psychiatry 1992;32:1-17
2. Willner P. Dopamine and depression: a review of recent evidence, ii: theoretical approaches. Brain Res 1983;287:225-236
3. Pearlson GD, Wong DF, Tune LE, et al. In vivo D2 dopamine receptor density in psychotic and nonpsychotic patients with bipolar disorder. Arch Gen Psychiatry 1995;52:471-477
4. Ebert D, Feistel H, Kaschka W, et al. Single photon emission computerized tomography assessment of cerebral dopamine D2 receptor blockade in depression before and after sleep deprivation - preliminary results. Biol Psychiatry 1994;35:880-885
5. Suhara T, Nakayama K, Inuoe O, et al. D1 dopamine receptor binding in mood disorders measured by positron emission tomography. Psychopharmacology 1992;106:14-18
6. Pearlson GD, Schlaepfer TE. Brain imaging in mood disorders. In: Bloom FE, Kupfer DJ, eds. Psychopharmacology: The Fourth Generation of Progress. New York, NY: Raven Press; 1995:1019-1028
7. Duffy JD, Coffey CE. The neurobiology of depression. In: Trimble J, Cummings J, eds. Contemporary Behavioral Neurology. Boston, Mass: Butterworth-Heinemann; 1997:275-288
8. Alexander GE, Crutcher MD, DeLong MR. Basal ganglia-thalamocortical circuits: parallel substrates for motor, oculomotor, 'prefrontal,' and 'limbic' functions. Prog Brain Res 1990;85:119-146
9. Swerdlow NR, Koob GF. Dopamine, schizophrenia, mania, and depression: toward a unified hypothesis of cortico-striato-pallido-thalamic function. Behav Brain Sci 1987;10:197-245
10. Smith GS, Dewey SL, Brodie JD, et al. Serotonergic modulation of dopamine measured with [11C]raclopride and PET in normal human subjects. Am J Psychiatry 1997;154:490-496
11. Modigh K, Balldin J, Eriksson E, et al. Increased responsiveness of dopamine receptors after ECT: a review of experimental and clinical evidence. In: Lerer B, Weiner RD, Belmaker RH, eds. ECT: Basic Mechanisms. London, England: John Libbey; 1984:18-27
12. Glue P, Costello MJ, Pert A, et al. Regional neurotransmitter responses after acute and chronic electroconvulsive shock. Psychopharmacology 1990; 100:60-65
13. McGarvey KA, Zis AP, Brown EE, et al. ECS-induced dopamine release: effects of electrode placement, anticonvulsant treatment, and stimulus intensity. Biol Psychiatry 1993;34:152-157
14. Muscat R, Papp M, Willner P. Antidepressant-like effects of dopamine agonists in an animal model of depression. Biol Psychiatry 1992;31:937-946
15. Agnoli A, Ruggieri S, Casacchia M. Restatement and perspectives of ergot alkaloids in clinical neurology and psychiatry. Pharmacology 1978;16 (suppl 1):174-188
16. Colonna L, Petit M, Lepine JP. Bromocriptine in affective disorders. J Affect Disord 1979;1:173-177
17. Nordin C, Siwers B, Bertilsson L. Bromocriptine treatment of depressive disorders: clinical and biochemical effects. Acta Psychiatr Scand 1981;64: 25-33
18. Silverstone T. Response to bromocriptine distinguishes bipolar from unipolar depressions. Lancet 1984;1:903-904
19. Wells BG, Marken PA. Bromocriptine in the treatment of depression. DICP, Ann Pharmacother 1989;23:600-601
20. Bouras N, Bridges PK. Bromocriptine and depression. Curr Med Res Opin 1982;8:150-153
21. Waehrens J, Gerlach J. Bromocriptine and imipramine in endogenous depression: a double-blind controlled trial in out-patients. J Affect Disord 1981;3:193-202
22. Theohar C, Fischer-Cornelssen K, Brosch H, et al. A comparative, multi-center trial between bromocriptine and amitriptyline in the treatment of endogenous depression. Arzneimittelforschung 1982;32:783-787
23. Post RM, Gerner RH, Carman JS, et al. Effects of a dopamine agonist piribedil in depressed patients. Arch Gen Psychiatry 1978;35:609-615
24. Chiarello RJ, Cole JO. The use of psychostimulants in psychiatry. Arch Gen Psychiatry 1987;44:286-295
25. Satel SL, Nelson JC. Stimulants in the treatment of depression: a critical review. J Clin Psychiatry 1989;50:241-249
26. Warneke L. Psychostimulants in psychiatry. Can J Psychiatry 1990;35: 3-10
27. Bouckoms A, Mangini L. Pergolide: an antidepressant adjuvant for mood disorders? New Clinical Drug Evaluation Unit; 1992; Boca Raton, Fla
28. Linet LS. Treatment of a refractory depression with a combination of fluoxetine and d-amphetamine [letter]. Am J Psychiatry 1989;146:803-804
29. Metz A, Shader RI. Combination of fluoxetine with pemoline in the treatment of major depressive disorder. Int Clin Psychopharmacol 1991;6: 93-96
30. Stoll AL, Pillay SS, Diamond L, et al. Methylphenidate augmentation of serotonin selective reuptake inhibitors: a case series. J Clin Psychiatry 1996;57:72-76
31. Feighner JP, Herbstein J, Damlouji N. Combined MAOI, TCA, and direct stimulant therapy of treatment-resistant depression. J Clin Psychiatry 1985; 46:206-209
32. Fawcett J, Kravitz HM, Zajecka JM, et al. CNS stimulant potentiation of monoamine oxidase inhibitors in treatment-refractory depression. J Clin Psychopharmacol 1991;11:127-132
33. Alpert JE, Maddox A, Nierenberg AA, et al. Attention deficit hyperactivity disorder in childhood among adults with major depression. Psychiatry Res 1996;62:213-219
34. Cole JO, Boling LA, Beake BJ. Stimulant drugs: medical needs, alternative indications and related problems. In: Cooper JR, Czechowicz DJ, Molinari SP, et al. Impact of Prescription Drug Diversion Control Systems on Medical Practice and Patient Care. Rockville, Md: National Institute on Drug Abuse; 1993. NIDA Monograph No. 131:89-108
35. Fawcett J, Busch KA. Stimulants in psychiatry. In: Schatzberg AF, Nemeroff CB, eds. The American Psychiatric Press Textbook of Psychopharmacology. Washington, DC: American Psychiatric Press; 1995: 417-435
36. AMA Drug Evaluations. Chicago, Ill: American Medical Association, 1993
37. Physicians' Desk Reference. Montvale, NJ: Medical Economics; 1997